Higher efavirenz plasma levels correlate with development of insomnia.
about
Efavirenz and the CNS: what we already know and questions that need to be answeredLong-term efavirenz autoinduction and its effect on plasma exposure in HIV patientsQuality of Sleep in an HIV Population on Antiretroviral Therapy at an Urban Tertiary Centre in Lagos, Nigeria.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceBurden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across China.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Insomnia symptoms and HIV infection among participants in the Women's Interagency HIV Study.Types of sleep problems in adults living with HIV/AIDS.Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphismPrevalence and factors associated with sleep disturbances among early-treated HIV-infected personsPharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.Efavirenz: a review.Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.Qualitative study of the quality of sleep in marginalized individuals living with HIV.The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.The pharmacologic management of insomnia in patients with HIV.Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.The impact of pharmacogenetics on HIV therapy.A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.Neuronal toxicity of efavirenz: a systematic review.Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Impact of pharmacogenetics on CNS side effects related to efavirenz.Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro.Trajectories of Sleep Disturbance Severity in HIV-Infected and Uninfected Veterans.Polyethylene glycolated PAMAM dendrimers-Efavirenz conjugates.Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.Discordant genotypic resistance and HIV-1 genetic diversity from paired plasma and cerebrospinal fluid samples in Chinese settings.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
P2860
Q28085028-06510727-6883-4CDB-91B1-0E4C648089E4Q28294491-9FE53F7B-5362-42B2-BA15-69D267E67510Q33607553-BF24B3D1-9946-4707-8849-DCCD490185FBQ33681426-EA640CF3-7EF4-4A3B-BE31-863723D2E443Q33807989-F05D3072-29F9-4150-8675-EEEC6E5AB7BCQ34443184-AF5B2E6F-15C0-42DD-9E32-BDD42371EEA6Q34464997-72CECD1D-0954-435B-8EB9-FB42198C2CD8Q34756398-E6EB8AD7-8F4D-4649-B035-DF69952CFF4CQ35114865-E0C87246-B611-4D41-99AE-D3761A2B28BAQ35132410-23BB3E3B-9FC5-4960-BC68-F79D119A08AFQ35364120-F58732E5-0D12-4D5A-9293-E25E1EC2A9D4Q35623512-9A81F9A0-4999-4A63-A9B9-81AA4DDDA8B1Q35696047-2557BBAF-271A-483F-B27B-1F52E0C9B0A9Q35827416-84C7C413-D8AF-4D98-8466-851633682CCAQ35906888-CAB71E29-399D-434B-971A-14E538689F25Q36468146-D69AC2E7-BB54-4D93-AF5B-8E2A768852DDQ36787311-D20962E8-AEC4-4EC7-AA49-2B303E609B68Q36922243-81522ED8-1C41-40CC-B41F-F10C45F5D8E8Q36943576-23F8D38B-E431-4763-BF99-30166C4FE5ADQ37174248-6ED263A0-E103-4404-9403-183BA686025AQ37234441-F149BAF3-5669-4804-B0C3-D61CC14B5B28Q37247762-84EA2878-83A9-4AA4-83DF-6E4F0FECB8ABQ37334180-13E96991-786A-430A-82C5-15F0251880C3Q37405140-B1DE19C2-B32A-4795-AB11-D938DD32A7C9Q37471061-AB0BFE9B-653C-4D1D-9441-39C71093A655Q38111430-9CB133F1-DE46-495E-A7A9-849B3B51F994Q38124394-3F8F86EF-3D67-4133-9EDB-67B3593C93F6Q38175870-7CB535EE-107B-476D-8475-1A3C46E9F1B0Q38377051-19F90AC2-EF98-40AD-89C7-49EE4EA06145Q38486729-E856EDDA-3947-4D84-900A-0A73908AABEFQ38554604-7B4AAD53-B655-4C4C-8675-BDB0548ABF1DQ39383647-C8F0BC95-29C3-4C6B-AC56-DEE0325EDA66Q40158060-A460F079-2136-4B4D-8A9E-BB0767EC8560Q40260140-EEFE45F8-E4D0-4363-890F-B875F1729346Q41939589-C8A74539-6A2E-48C2-B7A9-58108C0DB21BQ42210634-120DCE52-7E2C-45E6-BCC6-D844DE2F4BCDQ42278503-B7BA644E-E49F-4CD9-9D2A-56FE5AC42BE6Q42592784-73154582-876E-4B5B-AA32-2A69BEE5C2C8Q43074797-BC4EBB61-B757-454C-9D64-B22CDDE5FC55Q44238575-7614B69D-E17B-4B97-929F-BACD3F609B18
P2860
Higher efavirenz plasma levels correlate with development of insomnia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Higher efavirenz plasma levels correlate with development of insomnia.
@en
Higher efavirenz plasma levels correlate with development of insomnia.
@nl
type
label
Higher efavirenz plasma levels correlate with development of insomnia.
@en
Higher efavirenz plasma levels correlate with development of insomnia.
@nl
prefLabel
Higher efavirenz plasma levels correlate with development of insomnia.
@en
Higher efavirenz plasma levels correlate with development of insomnia.
@nl
P2093
P1476
Higher efavirenz plasma levels correlate with development of insomnia.
@en
P2093
D González de Requena
I Jiménez-Nácher
J González-Lahoz
P304
P356
10.1097/00126334-200112010-00015
P407
P577
2001-12-01T00:00:00Z